litlas
ログインアカウント作成

Tudor–Eliade Ciuleanu

2004–2026 年に発表

別表記
Tudor-Eliade Ciuleanu
109
論文数
37,956
被引用数
69
h 指数
102
i10 指数

被引用数

Tudor–Eliade Ciuleanu の年別被引用数1971 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 1 件2004 年: 被引用 9 件2005 年: 被引用 52 件2006 年: 被引用 134 件2007 年: 被引用 178 件2008 年: 被引用 174 件2009 年: 被引用 203 件2010 年: 被引用 214 件2011 年: 被引用 216 件2012 年: 被引用 198 件2013 年: 被引用 283 件2014 年: 被引用 201 件2015 年: 被引用 261 件2016 年: 被引用 277 件2017 年: 被引用 315 件2018 年: 被引用 417 件2019 年: 被引用 1,315 件2020 年: 被引用 1,344 件2021 年: 被引用 1,324 件2022 年: 被引用 1,053 件2023 年: 被引用 992 件2024 年: 被引用 1,553 件2025 年: 被引用 795 件2026 年: 被引用 15 件1972〜2000 年は被引用が無いため表示していません2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,740 件、この内訳の 23.5%中国: 引用元論文 2,189 件、この内訳の 13.8%イタリア: 引用元論文 928 件、この内訳の 5.8%イギリス: 引用元論文 767 件、この内訳の 4.8%フランス: 引用元論文 756 件、この内訳の 4.7%日本: 引用元論文 743 件、この内訳の 4.7%スペイン: 引用元論文 687 件、この内訳の 4.3%ドイツ: 引用元論文 686 件、この内訳の 4.3%カナダ: 引用元論文 562 件、この内訳の 3.5%オランダ: 引用元論文 390 件、この内訳の 2.5%韓国: 引用元論文 380 件、この内訳の 2.4%スイス: 引用元論文 377 件、この内訳の 2.4%
0%23.5%その他 23.3%

機関

分野

  • Medicine80.4%
  • Biochemistry, Genetics and Molecular Biology12.3%
  • Immunology and Microbiology4.4%
  • Engineering0.5%
  • Materials Science0.4%
  • Mathematics0.3%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers14.7%
  • Lung Cancer Treatments and Mutations11.5%
  • Lung Cancer Research Studies6.7%
  • Lung Cancer Diagnosis and Treatment5%
  • Cancer Genomics and Diagnostics4%
  • Immunotherapy and Immune Responses3.9%
  • その他54.2%

共著者

全論文

検索で開く
  1. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

    著者: Patrick M. Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Stephen R. Broderick, Julie R. Brahmer, Scott J. Swanson, Keith Kerr, Changli Wang, Tudor-Eliade Ciuleanu, Gene B. Saylors, Fumihiro Tanaka, Hiroyuki Ito, Ke-Neng Chen, Moishe Liberman, Everett E. Vokes, Janis M. Taube, Cecile Dorange, Junliang Cai, Joseph Fiore, Anthony Jarkowski, David Balli, Mark Sausen, Dimple Pandya, Christophe Y. Calvet, Nicolas Girard - New England Journal of Medicine 2022 被引用: 2,558

  2. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    著者: Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Pamela Salman, Pierre-Jean Souquet, Pedro De Marchi, Claudio Martín, M. Pérol, Arnaud Scherpereel, Shun Lü, Thomas John, David P. Carbone, S. Meadows–Shropshire, Shruti Agrawal, Abderrahim Oukessou, Jinchun Yan, Martin Reck - The Lancet Oncology 2021 被引用: 1,362

  3. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    著者: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 被引用: 3,137

  4. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    著者: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 被引用: 2,575

  5. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    著者: Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, László Urbán, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Płużański, Jacobus A. Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam - Journal of Clinical Oncology 2022 被引用: 381

  6. Perioperative Nivolumab in Resectable Lung Cancer

    著者: Tina Cascone, Mark M. Awad, Jonathan Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Nina Karaseva, Jarosław Kużdżał, Luboš Petruželka, Lin Wu, Jean-Louis Pujol, Hiroyuki Ito, Tudor–Eliade Ciuleanu, Ludmila de Oliveira Muniz Koch, Annelies Janssens, Aurelia Alexandru, Sabine Bohnet, Fedor V. Moiseyenko, Yang Gao, Yasutaka Watanabe, Cinthya Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Steven I. Blum, Mariano Provencio - New England Journal of Medicine 2024 被引用: 447

  7. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    著者: Eugene D. Kwon, Charles G. Drake, H. I. Scher, Karim Fizazi, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, C. Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen - The Lancet Oncology 2014 被引用: 1,496

  8. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    著者: Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol - The Lancet 2014 被引用: 1,308

  9. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

    著者: Robert L. Ferris, Robert I. Haddad, Caroline Even, Makoto Tahara, Mikhail Dvorkin, Tudor–Eliade Ciuleanu, Paul M. Clément, Ricard Mesı́a, С. И. Кутукова, Lyubov Zholudeva, Amaury Daste, Javier Caballero-Daroqui, Bhumsuk Keam, Ihor Vynnychenko, C. Lafond, Jagdish Shetty, Helen Mann, Jean Fan, Sophie Wildsmith, Nassim Morsli, Jérôme Fayette, Lisa Licitra - Annals of Oncology 2020 被引用: 365

  10. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    著者: Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 322

  11. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

    著者: Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah - The Lancet Oncology 2015 被引用: 955

  12. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

    著者: Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Felipe Reyes, P.-J. Souquet, Pedro De Marchi, Claudio Martín, M. Pérol, Arnaud Scherpereel, Shun Lü, Luis Paz‐Ares, David P. Carbone, Arteid Memaj, S. Marimuthu, X. Zhang, Phuong Tran, Thomas John - ESMO Open 2021 被引用: 188

  13. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

    著者: David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu, Scott Gettinger, Solange Peters, Leora Horn, Clarisse Audigier-Valette, N. Pardo Aranda, Óscar Juan, Ying Cheng, H. Zhang, Meiqi Shi, Alexander Luft, Juergen Wolf, Scott Antonia, Kazuhiko Nakagawa, Justin Fairchild, Christine Baudelet, Devangini K. Pandya, Parul Doshi, Han Chang, Martin Reck - Annals of Oncology 2021 被引用: 271

  14. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

    著者: Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour - New England Journal of Medicine 2005 被引用: 5,451

  15. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    著者: Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro, Sophie Cousin, Laura Bonanno, Egbert F. Smit, Alberto Chiappori, M.E. Olmedo, Ildikó Horváth, Christian Grohé, Anna F. Farago, José Antonio López-Vilariño, Martín Cullell-Young, Antonio Nieto, Noelia Vasco, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Enric Carcereny, Jaromı́r Roubec, Konstantinos Syrigos, Gregory Lo, I. Barneto, Anthony Pope, Amparo Martínez Sánchez, Joseph Kattan, Paul Zarogoulidis, Cornelius F. Waller, Helge Bischoff, Óscar Juan, Niels Reinmuth, Manuel Dómine, Luis Paz‐Ares - The Lancet Respiratory Medicine 2022 被引用: 120

  16. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

    著者: D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü - Journal of Clinical Oncology 2024 被引用: 135

  17. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    著者: Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor–Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd - The Lancet Oncology 2013 被引用: 526

  18. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

    著者: Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Óscar Juan, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, J. Menezes, Jacek Jassem, Светлана Проценко, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Żurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker R. Dakhil, Shun Lü, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone - Journal of Thoracic Oncology 2022 被引用: 97

  19. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

    著者: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, Eugene D. Kwon, Howard I. Scher, Winald R. Gerritsen, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Riccardo Danielli, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor–Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, M. Brent McHenry, Allen Chen, Christopher J. Logothetis - European Urology 2020 被引用: 175

  20. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

    著者: Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, Tudor–Eliade Ciuleanu, Caio Guilherme Pereira, Eva Muñoz‐Couselo, Fernanda Damian, Michael Schenker, Aldo Perfetti, Célèste Lebbé, G. Quéreux, Friedegund Meier, Brendan D. Curti, Carlos A. Rojas, Yull Arriaga, Hai-Su Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary Tagliaferri, Nikhil I. Khushalani - Journal of Clinical Oncology 2023 被引用: 72

  21. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

    著者: M. M. Heiss, P. Murawa, P. Koralewski, E. Kutarska, Olena Kolesnik, В. В. Іванченко, Alexander S. Dudnichenko, Birutė Aleknavičienė, Artūras Razbadauskas, Martin Gore, Elena Ganea‐Motan, Tudor–Eliade Ciuleanu, Pauline Wimberger, Alexander Schmittel, Barbara Schmalfeldt, Alexander Burges, Carsten Bokemeyer, Horst Lindhofer, Angelika Lahr, Simon L. Parsons - International Journal of Cancer 2010 被引用: 551

  22. Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

    著者: Mary O’Brien, Tudor–Eliade Ciuleanu, H. Tsekov, Yaroslav Shparyk, Branka Čučeviá, Gábor Juhász, Nicholas Thatcher, Graham Ross, G. Dane, T. Crofts - Journal of Clinical Oncology 2006 被引用: 639

  23. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    著者: Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman, Enriqueta Felip, Tudor–Eliade Ciuleanu, M.R. García Campelo, Kevin Jao, Fabrice Barlési, Stéphanie Bordenave-Juchereau, Erika Rijavec, László Urbán, Jean-Sébastien Aucoin, Cristina Zannori, Karim Vermaelen, Osvaldo Arén Frontera, Alessandra Curioni‐Fontecedro, Amparo Sánchez-Gastaldo, Óscar Juan, Helena Linardou, Elena Poddubskaya, David R. Spigel, Samreen Ahmed, Michele Maio, Sunney Li, Han Chang, Joseph Fiore, A. Acevedo, Luis Paz‐Ares - Journal for ImmunoTherapy of Cancer 2023 被引用: 73

  24. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

    著者: Martin Reck, Tudor–Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Żurawski, Sang‐We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Płużański, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martínez‐Martí, Koichi Azuma, Rita Axelrod, Luis Paz‐Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O’Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, Julie R. Brahmer - Journal of Thoracic Oncology 2023 被引用: 72